GlassScriptPhysician profile
Maynard R Holgado
NPI 1679526396
$14,334.79
in general payments reported to CMS, 2019-2025
55 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,354 · 2020: $1,729 · 2021: $2,351 · 2022: $2,352 · 2023: $1,936 · 2024: $2,057 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,548.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,456.96 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,385.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,282.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $914.15 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $882.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $792.83 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $665.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Daiichi Sankyo INC. | $596.17 | 2019-2025 | Injectafer |
| Amgen INC. | $528.96 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $513.39 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $510.42 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $439.57 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $412.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $360.66 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $351.56 | 2019-2025 | Zoryve |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maynard Holgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.